Phaseline

Companies › Adlai Nortye Biopharma

Adlai Nortye Biopharma: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AN4005–Phase 1Advanced Solid TumorNov 2026
AN8025
Multifunctional antibody fusion protein
–Phase 1Advanced Solid Tumor (Phase 1)Jul 2027
AN9025
Pan-RAS inhibitor that binds cyclophilin A (CypA) and forms a tri-complex with GTP-bound R
KRAS, NRAS, HRASPhase 1Solid Tumors (Phase 1)Jan 2028
AN4035
CEACAM5-targeting antibody-drug conjugate (ADC) delivering a pan-RAS(ON) inhibitor payload
CEACAM5, KRAS, NRAS, HRASPhase 1Solid Tumor (Phase I)Dec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04999384AN4005Phase 1Advanced Solid TumorOncologyNov 2026
NCT07639047AN8025Phase 1Advanced Solid Tumor (Phase 1)OncologyJul 2027
NCT07252479AN9025Phase 1Solid Tumors (Phase 1)OncologyJan 2028
NCT07686445AN4035Phase 1Solid Tumor (Phase I)OncologyDec 2028

From the company's SEC filings

Cash of $61m on 2024-12-31; operating cash outflow about $52m a year; runway about 14 months at that burn, to Mar 2026

Specialist investors

Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

KRAS (2) NRAS (2) HRAS (2) CEACAM5 (1)

Companies with the same targets

Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Roche Bristol-Myers Squibb Quanta Therapeutics Guangzhou JOYO Pharma Eli Lilly Shanghai YingLi Pharmaceutical Amgen Novartis

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.